Comparison 1. Prophylactic granulocytes versus no prophylactic granulocytes.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All‐cause mortality up to 30 days	7	437	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.63, 1.36]
1.1 Low‐dose granulocytes	3	144	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.64, 2.72]
1.2 Intermediate‐dose granulocytes	4	293	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.47, 1.16]
2 All‐cause mortality up to 100 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2.1 Granulocyte dose unknown	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 All‐cause mortality over 100 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Low‐dose granulocytes	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Mortality due to infection up to 30 days	6	286	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.33, 1.44]
4.1 Low‐dose granulocytes	3	144	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.46, 2.86]
4.2 Intermediate‐dose granulocytes	3	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.25 [0.06, 1.10]
5 Mortality due to infection up to 100 days	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
5.1 Granulocyte dose unknown	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 People with localised or systemic bacterial or fungal infections	9		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 Low‐dose granulocyte transfusions	4	204	Risk Ratio (M‐H, Fixed, 95% CI)	0.84 [0.58, 1.20]
6.2 Intermediate‐dose granulocyte transfusions	4	293	Risk Ratio (M‐H, Fixed, 95% CI)	0.40 [0.26, 0.63]
6.3 Unknown dose of granulocyte transfusion	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.61, 1.55]
7 People with bacteraemia or fungaemia	9	609	Risk Ratio (M‐H, Fixed, 95% CI)	0.45 [0.30, 0.65]
7.1 Low‐dose granulocyte transfusions	4	204	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.27, 0.96]
7.2 Intermediate‐dose granulocyte transfusions	4	293	Risk Ratio (M‐H, Fixed, 95% CI)	0.28 [0.14, 0.55]
7.3 Unknown dose of granulocyte transfusions	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.39, 1.61]
8 People with bacteraemia or fungaemia (excluding study that compared prophylactic granulocyte transfusions versus prophylactic broad‐spectrum antibiotics)	8	497	Risk Ratio (M‐H, Fixed, 95% CI)	0.37 [0.23, 0.59]
8.1 Low‐dose granulocyte transfusions	4	204	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.27, 0.96]
8.2 Intermediate‐dose granulocyte transfusions	4	293	Risk Ratio (M‐H, Fixed, 95% CI)	0.28 [0.14, 0.55]
9 People with localised bacterial or fungal infection	6	296	Risk Ratio (M‐H, Fixed, 95% CI)	0.75 [0.50, 1.14]
9.1 Low‐dose granulocyte transfusions	2	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.19, 1.11]
9.2 Intermediate‐dose granulocyte transfusions	3	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.38, 1.31]
9.3 Unknown dose of granulocyte transfusions	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	1.12 [0.54, 2.33]
10 People with localised bacterial or fungal infection (excluding study that compared prophylactic granulocyte transfusions versus prophylactic broad‐spectrum antibiotics)	5	184	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.37, 1.02]
10.1 Low‐dose granulocyte transfusions	2	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.19, 1.11]
10.2 Intermediate‐dose granulocyte transfusions	3	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.71 [0.38, 1.31]